000147334 001__ 147334
000147334 005__ 20240229112647.0
000147334 0247_ $$2doi$$a10.3174/ajnr.A6253
000147334 0247_ $$2pmid$$apmid:31601576
000147334 0247_ $$2ISSN$$a0195-6108
000147334 0247_ $$2ISSN$$a1936-959X
000147334 0247_ $$2altmetric$$aaltmetric:68278553
000147334 037__ $$aDKFZ-2019-02455
000147334 041__ $$aeng
000147334 082__ $$a610
000147334 1001_ $$00000-0001-5025-3709$$aJaju, A.$$b0
000147334 245__ $$aMRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Children's Oncology Group ACNS0332 Trial.
000147334 260__ $$aOak Brook, Ill.$$bSoc.$$c2019
000147334 3367_ $$2DRIVER$$aarticle
000147334 3367_ $$2DataCite$$aOutput Types/Journal article
000147334 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1573821145_28760
000147334 3367_ $$2BibTeX$$aARTICLE
000147334 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147334 3367_ $$00$$2EndNote$$aJournal Article
000147334 500__ $$a40(11):1796-1803
000147334 520__ $$aSupratentorial primitive neuroectodermal tumors and pineoblastomas have traditionally been grouped together for treatment purposes. Molecular profiling of these tumors has revealed a number of distinct entities and has led to the term 'CNS-primitive neuroectodermal tumors' being removed from the 2016 World Health Organization classification. The purpose of this study was to describe the MR imaging findings of histologically diagnosed primitive neuroectodermal tumors and pineoblastomas and correlate them with molecular diagnoses and outcomes.Histologically diagnosed primitive neuroectodermal tumors and pineoblastomas were enrolled in this Children's Oncology Group Phase III trial, and molecular classification was retrospectively completed using DNA methylation profiling. MR imaging features were systematically studied and correlated with molecular diagnoses and survival.Of the 85 patients enrolled, 56 met the inclusion criteria, in whom 28 tumors were in pineal and 28 in nonpineal locations. Methylation profiling revealed a variety of diagnoses, including pineoblastomas (n = 27), high-grade gliomas (n = 17), embryonal tumors (n = 7), atypical teratoid/rhabdoid tumors (n = 3), and ependymomas (n = 2). Thus, 39% overall and 71% of nonpineal tumor diagnoses were discrepant with histopathology. Tumor location, size, margins, and edema were predictors of embryonal-versus-nonembryonal tumors. Larger size and ill-defined margins correlated with poor event-free survival, while metastatic disease by MR imaging did not.In nonpineal locations, only a minority of histologically diagnosed primitive neuroectodermal tumors are embryonal tumors; therefore, high-grade glioma or ependymoma should be high on the radiographic differential. An understanding of molecularly defined tumor entities and their relative frequencies and locations will help the radiologist make more accurate predictions of the tumor types.
000147334 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000147334 588__ $$aDataset connected to CrossRef, PubMed,
000147334 7001_ $$00000-0002-3923-1135$$aHwang, E. I.$$b1
000147334 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b2$$udkfz
000147334 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b3$$udkfz
000147334 7001_ $$aChavez, L.$$b4
000147334 7001_ $$0P:(DE-He78)b0b3740107f746e09dc23fdf25eb0629$$aBrabetz, Sebastian$$b5
000147334 7001_ $$00000-0003-2819-4946$$aBillups, C.$$b6
000147334 7001_ $$aLi, Y.$$b7
000147334 7001_ $$00000-0002-5693-035X$$aFouladi, M.$$b8
000147334 7001_ $$00000-0001-9413-7531$$aPacker, R. J.$$b9
000147334 7001_ $$00000-0002-5447-5322$$aPfister, S. M.$$b10
000147334 7001_ $$00000-0001-5990-6534$$aOlson, J. M.$$b11
000147334 7001_ $$00000-0001-5519-9326$$aHeier, L. A.$$b12
000147334 773__ $$0PERI:(DE-600)2025541-X$$a10.3174/ajnr.A6253$$gp. ajnr;ajnr.A6253v1$$n11$$p1796-1803$$tAmerican journal of neuroradiology$$v40$$x1936-959X$$y2019
000147334 909CO $$ooai:inrepo02.dkfz.de:147334$$pVDB
000147334 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000147334 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aExternal Institute$$b3$$kExtern
000147334 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-5447-5322$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000147334 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000147334 9141_ $$y2019
000147334 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147334 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000147334 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J NEURORADIOL : 2017
000147334 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147334 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000147334 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000147334 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147334 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147334 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000147334 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000147334 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000147334 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000147334 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000147334 980__ $$ajournal
000147334 980__ $$aVDB
000147334 980__ $$aI:(DE-He78)B062-20160331
000147334 980__ $$aUNRESTRICTED